← FDA DRUG APPROVALS
FDA ANDA · ANDA219881
DOXORUBICIN HYDROCHLORIDE LIPOSOME
doxorubicin hydrochloride
Sponsor: QILU PHARM HAINAN
APPLICATION
ANDA219881
TYPE
ANDA
ORIGINAL APPROVAL
2026-02-03
LATEST ACTION
2026-02-03
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE, LIPOSOMAL
MARKETING STATUS
Prescription
Products
DOXORUBICIN HYDROCHLORIDEPrescription
DOXORUBICIN HYDROCHLORIDE 20MG/10ML (2MG/ML) · INJECTABLE, LIPOSOMAL · INJECTION
DOXORUBICIN HYDROCHLORIDEPrescription
DOXORUBICIN HYDROCHLORIDE 50MG/25ML (2MG/ML) · INJECTABLE, LIPOSOMAL · INJECTION
Approval history
2026-02-03UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.